NMC
JSPR icon

Nine Masts Capital’s Jasper Therapeutics JSPR Stock Holding History

Nine Masts Capital’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,165
Closed -$38.7K – 238
2026
Q1 		$38.7K Buy
+44,165
New +$61.3K 0.01% 186

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nine Masts Capital's JSPR Position: Q2 2026 in Review

Nine Masts Capital sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 44,165 shares — an estimated $38.7K sold.

Nine Masts Capital first reported a position in JSPR in Q1 2026 and held it in 1 quarter. The position peaked at $38.7K in Q1 2026. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Nine Masts Capital reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nine Masts Capital sold 44,165 Jasper Therapeutics shares in Q2 2026, an estimated $38.7K.
  • Nine Masts Capital first reported a position in Jasper Therapeutics in Q1 2026 and held it in 1 quarter.
  • Nine Masts Capital's Jasper Therapeutics position peaked at $38.7K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.